New ALS drug PrimeC shows promise in Mid-Stage trial
Disease control
Completed
This study tested an experimental drug called PrimeC in 69 people with ALS (Lou Gehrig's disease). Participants took PrimeC or a placebo twice daily for 6 months, and all could continue on the drug for another 12 months. The goal was to check safety and see if PrimeC slows diseas…
Phase: PHASE2 • Sponsor: NeuroSense Therapeutics Ltd. • Aim: Disease control
Last updated May 17, 2026 13:08 UTC